IL215709A - Chk1 inhibitors for providing a patient with cancer to increase DNA-damaging factors - Google Patents
Chk1 inhibitors for providing a patient with cancer to increase DNA-damaging factorsInfo
- Publication number
- IL215709A IL215709A IL215709A IL21570911A IL215709A IL 215709 A IL215709 A IL 215709A IL 215709 A IL215709 A IL 215709A IL 21570911 A IL21570911 A IL 21570911A IL 215709 A IL215709 A IL 215709A
- Authority
- IL
- Israel
- Prior art keywords
- potentiating
- cancer
- administration
- patient
- dna damaging
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16856309P | 2009-04-11 | 2009-04-11 | |
| PCT/US2010/030634 WO2010118390A1 (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL215709A0 IL215709A0 (en) | 2012-01-31 |
| IL215709A true IL215709A (en) | 2017-06-29 |
Family
ID=42651200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL215709A IL215709A (en) | 2009-04-11 | 2011-10-11 | Chk1 inhibitors for providing a patient with cancer to increase DNA-damaging factors |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2416773B1 (enExample) |
| JP (2) | JP5805071B2 (enExample) |
| KR (1) | KR101676062B1 (enExample) |
| CN (1) | CN102612365B (enExample) |
| AU (1) | AU2010233122B2 (enExample) |
| BR (1) | BRPI1013920A2 (enExample) |
| CA (1) | CA2758300C (enExample) |
| ES (1) | ES2608656T3 (enExample) |
| IL (1) | IL215709A (enExample) |
| MX (1) | MX341368B (enExample) |
| NZ (1) | NZ596125A (enExample) |
| RU (1) | RU2567044C2 (enExample) |
| SG (3) | SG10201900212QA (enExample) |
| WO (1) | WO2010118390A1 (enExample) |
| ZA (1) | ZA201108273B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009089352A1 (en) | 2008-01-08 | 2009-07-16 | Array Biopharma Inc. | Pyrrolopyridines as kinase inhibitors |
| JP5608098B2 (ja) | 2008-01-09 | 2014-10-15 | アレイ バイオファーマ、インコーポレイテッド | キナーゼ阻害薬としてのピラゾロピリジン |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2012074754A1 (en) | 2010-11-16 | 2012-06-07 | Array Biopharma Inc. | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2015053402A1 (ja) | 2013-10-11 | 2015-04-16 | 国立大学法人東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| WO2020150417A2 (en) * | 2019-01-17 | 2020-07-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
| KR102285996B1 (ko) * | 2019-08-08 | 2021-08-05 | 차의과학대학교 산학협력단 | 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도 |
| WO2021113661A1 (en) | 2019-12-05 | 2021-06-10 | Seagen Inc. | Amorphous and polymorphic form of a specific chk1 inhibitor |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| CN1882342A (zh) * | 2003-09-17 | 2006-12-20 | 艾科斯有限公司 | Chk1抑制剂在控制细胞增殖中的应用 |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| RU2409361C2 (ru) * | 2006-04-04 | 2011-01-20 | Пфайзер Продактс Инк. | КОМБИНИРОВАННАЯ ТЕРАПИЯ (2R,Z)-2-АМИНО-2-ЦИКЛОГЕКСИЛ-N-(5-(1-МЕТИЛ-1Н-ПИРАЗОЛ-4-ИЛ)-1-ОКСО-2,6-ДИГИДРО-1Н-[1,2]ДИАЗЕПИНО[4,5,6-cd]ИНДОЛ-8-ИЛ)АЦЕТАМИДОМ |
| US20100143332A1 (en) * | 2006-11-17 | 2010-06-10 | Schering Corporation | Combination therapy for proliferative disorders |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
-
2010
- 2010-04-09 SG SG10201900212QA patent/SG10201900212QA/en unknown
- 2010-04-09 KR KR1020117026769A patent/KR101676062B1/ko not_active Expired - Fee Related
- 2010-04-09 AU AU2010233122A patent/AU2010233122B2/en not_active Ceased
- 2010-04-09 NZ NZ596125A patent/NZ596125A/xx not_active IP Right Cessation
- 2010-04-09 SG SG2011075520A patent/SG175242A1/en unknown
- 2010-04-09 WO PCT/US2010/030634 patent/WO2010118390A1/en not_active Ceased
- 2010-04-09 CN CN201080025806.6A patent/CN102612365B/zh not_active Expired - Fee Related
- 2010-04-09 MX MX2011010675A patent/MX341368B/es active IP Right Grant
- 2010-04-09 SG SG10201404012RA patent/SG10201404012RA/en unknown
- 2010-04-09 BR BRPI1013920A patent/BRPI1013920A2/pt not_active Application Discontinuation
- 2010-04-09 JP JP2012504909A patent/JP5805071B2/ja not_active Expired - Fee Related
- 2010-04-09 EP EP10721579.0A patent/EP2416773B1/en active Active
- 2010-04-09 ES ES10721579.0T patent/ES2608656T3/es active Active
- 2010-04-09 RU RU2011145773/15A patent/RU2567044C2/ru active
- 2010-04-09 CA CA2758300A patent/CA2758300C/en active Active
-
2011
- 2011-10-11 IL IL215709A patent/IL215709A/en active IP Right Grant
- 2011-11-10 ZA ZA2011/08273A patent/ZA201108273B/en unknown
-
2014
- 2014-07-29 JP JP2014153687A patent/JP2014198741A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2011145773A (ru) | 2013-05-20 |
| JP5805071B2 (ja) | 2015-11-04 |
| SG10201404012RA (en) | 2014-09-26 |
| EP2416773A1 (en) | 2012-02-15 |
| MX341368B (es) | 2016-08-17 |
| SG10201900212QA (en) | 2019-02-27 |
| AU2010233122A1 (en) | 2011-11-24 |
| IL215709A0 (en) | 2012-01-31 |
| EP2416773B1 (en) | 2016-09-28 |
| JP2012523435A (ja) | 2012-10-04 |
| BRPI1013920A2 (pt) | 2016-04-05 |
| AU2010233122B2 (en) | 2015-09-17 |
| ES2608656T3 (es) | 2017-04-12 |
| WO2010118390A1 (en) | 2010-10-14 |
| JP2014198741A (ja) | 2014-10-23 |
| RU2567044C2 (ru) | 2015-10-27 |
| CN102612365A (zh) | 2012-07-25 |
| CA2758300C (en) | 2017-07-25 |
| NZ596125A (en) | 2012-08-31 |
| CN102612365B (zh) | 2017-04-12 |
| KR101676062B1 (ko) | 2016-11-14 |
| SG175242A1 (en) | 2011-11-28 |
| ZA201108273B (en) | 2013-07-31 |
| CA2758300A1 (en) | 2010-10-14 |
| KR20120004523A (ko) | 2012-01-12 |
| MX2011010675A (es) | 2012-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL215709A (en) | Chk1 inhibitors for providing a patient with cancer to increase DNA-damaging factors | |
| IL268475A (en) | n-acetyl mannosamine as a medical preparation | |
| IL234624A0 (en) | Compounds for use as a drug to treat a solid tumor in a patient | |
| IL215815A0 (en) | Injection catheter for delivering a therapeutic agent into a substrate | |
| IL219073A (en) | A drug combination for cancer treatment | |
| EP2343066A4 (en) | THERAPEUTIC AGENT FOR HEPATITIS C | |
| GB0908957D0 (en) | Therapeutic agents | |
| EP2275135A4 (en) | THERAPY FOR HEPATIC CANCER | |
| PL2280717T3 (pl) | Środek terapeutyczny dla chorób beztlenowych | |
| IL215368A0 (en) | Therapeutic uses of quinazolinedione derivatives | |
| IL209006A0 (en) | Therapeutic agent for male sterility | |
| EP2184073A4 (en) | AGAINST PROTEASE HEMMER RESISTANT CANCER THERAPEUTICS | |
| GB0900484D0 (en) | Therapeutic agent | |
| EP2601954A4 (en) | THERAPEUTIC FOR DISEASES | |
| PT2403856E (pt) | Derivados de metilendioxibenzo[i]fenantridina utilizados para tratar o cancro | |
| EP2641609A4 (en) | THERAPEUTIC AGENT FOR MUSCLE DYSTROPHY | |
| PT2305654E (pt) | Agente terapêutico para a dor relacionada com o cancro | |
| GB0910493D0 (en) | Therapeutic agents | |
| GB0919821D0 (en) | Therapeutic agents | |
| GB0919824D0 (en) | Therapeutic agents | |
| GB0914533D0 (en) | Therapeutic agents | |
| GB0915586D0 (en) | Therapeutic agents | |
| GB0919829D0 (en) | Therapeutic agents | |
| GB0919819D0 (en) | Therapeutic agents | |
| GB0902450D0 (en) | Therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |